Abstract:Tamoxifen improves the overall survival rate in hormone receptor-positive breast cancer patients. However, despite the fact that it exerts antagonistic effects on the ERα, it can act as a partial agonist, resulting in tumor growth in estrogen-sensitive tissues. In this study, highly functionalized 5-hydroxy-2H-pyrrol-2-ones were synthesized and evaluated by using ERα- and phenotype-based screening assays. Compounds 32 and 35 inhibited 17β-estradiol (E2)-stimulated ERα-mediated transcription of the luciferase reporter gene in breast cancer cells without inhibition of the transcriptional activity mediated by androgen or glucocorticoid receptors. Compound 32 regulated E2-stimulated ERα-mediated transcription by partial antagonism, whereas compound 35 caused rapid and non-competitive inhibition. Monitoring of 2D and 3D cell growth confirmed potent antitumoral effects of both compounds on ER-positive breast cancer cells. Furthermore, compounds 32 and 35 caused apoptosis and blocked the cell cycle of ER-positive breast cancer cells in the sub-G1 and G0/G1 phases. Interestingly, compound 35 suppressed the functional activity of ERα in the uterus, as demonstrated by the inhibition of E2-stimulated transcription of estrogen and progesterone receptors and alkaline phosphatase enzymatic activity. Compound 35 showed a relatively low binding affinity with ERα. However, its antiestrogenic effect was associated with an increased polyubiquitination and a reduced protein expression of ERα. Clinically relevant, a possible combinatory therapy with compound 35 may enhance the antitumoral efficacy of 4-hydroxy-tamoxifen in ER-positive breast cancer cells. In silico ADME predictions indicated that these compounds exhibit good drug-likeness, which, together with their potential antitumoral effects and their lack of estrogenic activity, offers a pharmacological opportunity to deepen the study of ER-positive breast cancer treatment.

Development of Thieno[3 ',2 ':5,6]Thiopyrano[4,3-C]pyrazole-3-carboxamide Derivatives As the Estrogen Receptor Ligands: Synthesis, Characterization and Biological Activity

Prenylflavonoids as nonsteroidal phytoestrogens and related structure-activity relationships.

Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide.

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Synthesis and Anti-Tumor Activity of 1,4-Dihydrothieno[3',2':5,6]Thiopyrano[4,3-c]pyrazole-3-carboxylic Amide Derivatives

Synthesis, Characterization of a Series of Daidzein Derivatives As Selective Estrogen Receptor Modulator

Benzothiophene Derivatives As Selective Estrogen Receptor Covalent Antagonists: Design, Synthesis and Anti-Erα Activities.

Synthesis and Biological Evaluation of 2,3-Diaryl Isoquinolinone Derivatives As Anti-Breast Cancer Agents Targeting ERα and VEGFR-2.

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Synthesis and Estrogen-Like Activity of Resveratrol Analogues

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.

Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

Synthesis and Characterization of a Series of Genistein Derivatives As Selective Estrogen Receptor Modulators

Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure.

Structure-activity Relationships of 2, 4-Disubstituted Pyrimidines As Dual ERα/VEGFR-2 Ligands with Anti-Breast Cancer Activity.

Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors

Discovery of Highly Functionalized 5-hydroxy-2H-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen

Synthesis, Characterization and Biological Activity of Tetrahydrobenzo[4,5]thieno[2,3-D]pyrimidine Derivatives As Epidermal Growth Factor Receptor Inhibitors

Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.

Design, Synthesis and Biological Evaluation of Novel Indone Derivatives As Selective ERβ Modulators

Design, synthesis and biological activity against estrogen receptor-dependent breast cancer of furo[1]benzofuran derivatives